Bob Mecca joined BeiGene in July 2021 as Senior Vice President, Finance. In this role, he oversees Global Finance Operations and Procurement and is responsible for enhancing finance and procurement capabilities to support the continued growth and success of the company. Mr. Mecca brings more than 20 years of experience in the biopharmaceutical industry leading global finance teams across commercial, R&D, manufacturing, and corporate organizations. Most recently, he served as the Senior Vice President, Commercialization Finance at Bristol Myers Squibb where he oversaw the global commercial and medical organizations. Prior to that role, Mr. Mecca held leadership positions as Vice President of Finance covering R&D, Global Manufacturing & Supply Chain, and International Commercial Operations at Bristol Myers Squibb. He started his career in technology and operations consulting at Arthur Andersen. He earned an M.B.A. from the Wharton School of the University of Pennsylvania and his undergraduate degree in accounting from Loyola University of Maryland.

Clare Fisher joined BeiGene in July 2021 as SVP Business Development and Mergers & Acquisitions, bringing over 20 years of experience in healthcare, including leadership roles in corporate and business development, M&A, and strategy. Prior to joining Beigene, Ms. Fisher served as Kaleido Bioscience’s Chief Business Officer, a company dedicated to targeting the microbiome to treat a variety of diseases. Ms. Fisher previously also held senior global roles at Shire plc, Cubist Pharmaceuticals, Blueprint Medicines, and Genzyme Corporation leading collaborations, licensing, M&A, investments and divestments across many technologies and therapeutic areas. Ms. Fisher holds a B.S. in Biochemistry from the University of Bath, as well as an M.B.A. from Henley Management College in the U.K.

Guillaume Vignon, Ph.D., joined BeiGene in 2018 as our Senior Vice President, Business Development. Dr. Vignon formerly held the position of Vice President, Global Head Oncology and Immuno-Oncology Licensing & Business Development at Merck KGaA/EMD Serono. In this position, Dr. Vignon led a team of business development professionals responsible for structuring and negotiating terms of licensing agreements for oncology and immuno-oncology assets from discovery to commercial stage. As part of his mandate, he provided business development expertise and strategic input into the Oncology strategy. Throughout his career at Merck KGaA, Dr. Vignon forged and successfully established several strategic partnerships in the fields of Immuno-Oncology, Oncology, Companion Diagnostic, and Antibody Discovery with academia, biotech, and pharma. Dr. Vignon holds a Ph.D. in Biochemistry and Molecular Biology from the University of Paris 6/ Institut Pasteur, Paris, France and an MBA from Hult International Business School, Cambridge, MA.

Christiane Langer joined BeiGene in August 2021 as Senior Vice President of Global Medical Affairs. She is passionate about patients, groundbreaking science, people-oriented leadership, and building meaningful, sustainable connections. Prior to joining Beigene, Christiane served as SVP, Global Medical Affairs at AtaraBio, VP of Global Medical Affairs at Agios Pharmaceuticals, and worked in leading medical positions for Roche/Genentech in both the United States and Germany. In these roles, she built and managed medical affairs teams, led successful launches, built strong relationships, and established deep expertise around various hematology and oncology-related indications as well as cell therapy. Before that, Christiane held positions of increasing responsibility at Bristol-Myers Squibb in the United States and Europe.

Christiane earned her M.D. from the University of Freiburg, Germany and spent her residency in obstetrics and gynecology with a focus on gynecologic oncology at the University Hospital Hannover, Germany. She completed a postdoc on apoptosis research in breast cancer in Dr. John Reed’s lab at the Burnham Institute in La Jolla, CA.

Kevin Mannix joined BeiGene in December 2021 as Senior Vice President, Investor Relations. In this role he leads our global investor relations function. Mr. Mannix has extensive global investor relations experience, having joined BeiGene from Teva Pharmaceuticals Industries Ltd., as Senior Vice President of Investor Relations. Mr. Mannix joined Teva as the company’s first dedicated investor relations professional in North America and held several positions of increasing responsibility over 18 years with the company.

Prior to Teva, Kevin spent nine years working at several investor relations and financial communications consultancies, including Thomson Financial/Carson and Citigate Dewe Rogerson.

Kevin earned a Bachelor of Arts degree in History from Siena College in Albany, New York. He is currently working toward a Master of Science in Finance at Saint Joseph's University in Philadelphia, Pennsylvania.

John V. Oyler is our Co-Founder and Chairman, and has served as our Chief Executive Officer and a member of our Board of Directors since 2010. From 2005 to 2009, Mr. Oyler served as President and Chief Executive Officer of BioDuro, LLC, a drug discovery outsourcing company, which was acquired by Pharmaceutical Product Development Inc. in 2010. From 2002 to 2004, Mr. Oyler served as Chief Executive Officer of Galenea Corp., a biopharmaceutical company dedicated to the discovery of novel therapies for central nervous system diseases, which initially were developed at Massachusetts Institute of Technology. From 1997 to 2002, Mr. Oyler was a Founder and the President of Telephia, Inc. which was sold to The Nielsen Company in 2007. From 1997 to 1998, Mr. Oyler served as Co-Chief Executive Officer of Genta Incorporated (NASDAQ: GNTA), an oncology‑focused biopharmaceutical company. Mr. Oyler joined the Board of Directors of the Biotechnology Innovation Organization (BIO) in 2019 and is a member of its Health Section Governing Board. He began his career as a management consultant at McKinsey & Company. Mr. Oyler received his B.S. from Ma ssachusetts Institute of Technology and MBA from Stanford University.

Xiaodong Wang, Ph.D., is our Co-Founder and has served as the Chairman of our Scientific Advisory Board since 2011. Dr. Wang became a member of our Board of Directors in February 2016. Dr. Wang has served as the founding Director of the National Institute of Biological Sciences in Beijing since 2003 and became its Director and Investigator in 2010. Previously, he was a Howard Hughes Medical Institute Investigator from 1997 to 2010 and held the position of the George L. MacGregor Distinguished Chair Professor in Biomedical Sciences at the University of Texas Southwestern Medical Center in Dallas, Texas from 2001 to 2010. In 2004, Dr. Wang founded Joyant Pharmaceuticals, Inc., a venture capital-backed biotechnology company focused on the development of small molecule therapeutics for cancer. Dr. Wang received his Ph.D. in Biochemistry from the University of Texas Southwestern Medical Center and B.S. in Biology from Beijing Normal University. Dr. Wang has been a member of the National Academy of Science, USA, since 2004 and a foreign associate of the Chinese Academy of Sciences since 2013.

Xiaobin Wu, Ph.D., joined BeiGene in 2018 and currently serves as President, Chief Operating Officer, and General Manager of China. Dr. Wu was previously the Country Manager of Pfizer China and the Regional President of Pfizer Essential Health for Greater China from October 2009 to April 2018. Under Dr. Wu’s leadership, Pfizer expanded its portfolio and organization, grew sales meaningfully, initiated a range of innovative marketing programs, and established its position as a leading multinational pharmaceutical company in China. Prior to Pfizer, Dr. Wu served as President and Managing Director of Wyeth China and Hong Kong from August 2004 to October 2009. Before Wyeth, Dr. Wu was General Manager of Bayer Healthcare in China from 2001 to 2004. He started his career in 1992 in sales and marketing with Bayer in Germany. Dr. Wu received a Ph.D. in Biochemistry and Pharmacology and a master’s degree in Molecular Biology from the University of Konstanz in Germany.

Julia Wang joined BeiGene in June 2020 and currently serves as Chief Financial Officer. In this role, she will partner across the enterprise to optimize intrinsic value creation through greater financial discipline.  Ms. Wang has extensive global finance experience across biotech, pharmaceutical, medical devices, diagnostic testing, and consumer products. She was most recently Senior Vice President, Global Business Finance, Corporate Finance and Corporate FP&A at Alexion Pharmaceuticals, and prior to that position she served in various leadership roles at Quest Diagnostics. Previously, Ms. Wang spent over five years at Johnson & Johnson leading finance at several operating companies, including Xian-Janssen Pharmaceutical, J&J’s pharmaceutical business in China. She received an MBA from Fuqua School of Business at Duke University and a B.A. in British Language and Literature from Shandong Normal University.

Lai Wang, Ph.D., is our Global Head of R&D. Dr. Wang joined BeiGene in the early days of the company, 2011. His role has changed over the years within the organization, initially heading the biomarker and in vivo pharmacology groups. In 2013, he supported the clinical programs in the role of clinical biomarkers and translational research. In 2016, he was appointed as the head of China development, responsible for the clinical development in Asian-pacific region. Prior to joining BeiGene, Dr. Wang was the director of research at Joyant Pharmaceuticals, a biotech company based in Dallas, Texas. Dr. Wang received his B.S. from Fudan University and Ph.D. from University of Texas Health Science Center at San Antonio, and had post-doc training with Dr. Xiaodong Wang at Howard Hughes Medical Institute. Dr. Wang had over 20 years of experience in oncology field and over 10 years of experience in pharmaceutical industry on both research and development.

Melika Davis joined BeiGene in August 2019 as Senior Vice President and Global Head, Clinical Operations. In this role, she leads the overall strategy for the Global Clinical Operations organization and oversees the management and execution of all clinical trials at BeiGene. With a career dedicated to transforming clinical trials, Ms. Davis has built and grown successful global organizations that have brought 20 medical products to the market. Prior to joining BeiGene, she spent 15 years at Novartis leading its clinical monitoring operations group and served most recently as Senior Vice President and Global Head of Drug Development Quality. Previously, Ms. Davis worked at Schering Plough for 13 years in roles of increasing responsibilities in research and development. She received an M.S. in Molecular Biology and a B.S. from Texas Women’s University in Dallas and a License de Physiologie from the University of Sciences in Nice, France.

Diana Lee Francis joined BeiGene in June 2017 as Vice President and Global Head, Quality and Regulatory Compliance. In this role, Ms. Francis is responsible for global quality strategy and oversees global regulatory compliance in laboratory, clinical, pharmacovigilance, manufacturing, and distribution practices. An established leader in pharmaceutical quality and compliance, she has extensive experience in building comprehensive internal and external programs and streamlining key business processes for quality assurance. Prior to joining BeiGene, Ms. Francis has served as quality function leader in companies including Medivation, Theravance, Roche, and Genentech, and has been involved in the successful commercialization of more than 10 pharmaceutical products. She received a B.S. in Biochemistry from University of California, Berkeley.

John Freeman joined BeiGene in December 2019 as Chief Safety Officer and Senior Vice President, Global Patient Safety. In this role, Mr. Freeman is responsible for ensuring the effectiveness of BeiGene’s patient safety strategy across developmental and commercial settings. Prior to his appointment at BeiGene, Mr. Freeman spent more than 30 years building high performing, global, innovative patient safety functions at GSK, Amgen and Celgene. He served on Celgene’s global operating and management committees. Mr. Freeman holds a qualifying Law Degree from the London College of Law, an MSc in Clinical Research from the University of Wales and a BSc in Pharmacology from the University of Leeds, UK.

Angus Grant, Ph.D., joined BeiGene in June 2020 as Chief Business Executive, bringing in more than 25 years of experience across multiple key functions in the biotech industry, including business development, alliance management, research and development, and regulatory affairs . In this role, Dr. Grant oversees strategy, business development and alliance management, and helps drive external innovation and investment in other companies to guide BeiGene’s global growth strategy. Prior to joining us, Dr. Grant was the CEO of the Dementia Discovery Fund (DDF), a specialist venture capital fund focused on therapeutics for age-related dementias and neurodegenerative disease. Before that, Dr. Grant spent 12 years at Celgene (now a Bristol Myers Squibb company) serving various executive roles, including Corporate Vice President of Business Development and Vice President, Regulatory Affairs. Earlier in his career, Dr. Grant worked in business development and regulatory roles at Novartis, Merck KGaA, Rhone Poulanc-Rohrer, SmithKline Beecham, and the U.S. Food and Drug Administration’s Center for Biologics. He currently serves as the Chairman of the Board for Toronto Innovation and Acceleration Partners. Dr. Grant received a bachelor’s degree from the University of Richmond and a Ph.D. in Anatomy and Immunology from the Medical College of Virginia, and completed his postdoctoral training at the National Cancer Institute.

Michael Garvey joined BeiGene in 2018 and currently serves as Global Head of Technical Operations, bringing more than 20 years of industry experience to the company.  Mr. Garvey held various executive, technical, and operational leadership positions in biopharmaceutical companies in the U.S., Asia, and Europe. Most recently, Mr. Garvey served as a founding Executive member and Vice President of Samsung Biologics Manufacturing. While at Samsung Biologics, Mr. Garvey helped design, validate, technology transfer, operate, and successfully licensed an impressive +14 novel medicines in the largest Drug Substance facility (362,000L of capacity) in a single location. Prior joining Samsung Biologics, Mr. Garvey served as the Director in Drug Substance at Shire Human Genetic Therapies, now Takeda, supporting unmet market needs for enzyme-replacement therapies such as Velaglucerase alpha, Agalsidase alfa, and Elaprase.  Before Shire Human Genetic Therapies, Mr. Garvey served in various manufacturing leadership roles at Genentech, a subsidiary of Roche, in Drug Substance and Drug Product to manufacture Avastin, Rituxan, Herceptin, and more. Mr. Garvey began his career with Aventis, a subsidiary of Sanofi, as a Chemical Engineer and Manager of Drug Product where he participated and led the organization out of an U.S. Food Drug Agency Consent Decree. 

Graham Hardiman joined BeiGene in March 2021 as Senior Vice President, Global Human Resources. Mr. Hardiman brings more than 30 years of experience in HR to BeiGene, having joined the Company from Pfizer, where he served as a Senior Vice President and was responsible globally for talent acquisition, talent management, performance management, learning and development and diversity. Prior to that he was responsible for the HR team supporting Pfizer’s Oncology and Rare Disease franchises. Mr. Hardiman joined Pfizer from Wyeth and was initially based in the U.K., moving to Madrid Spain in 2009, and the U.S. in 2011. Prior to joining Pfizer, Mr. Hardiman worked in HR for Siebel, Computer Associates, EMC, and Telefonica.

Jaspreet Jaggi, M.D., Ph.D.,joined BeiGene in October 2020 as Senior Vice President and Head, Clinical Portfolio Strategy. In this role, Dr. Jaggi is responsible for scientific and strategic evaluation, and clinical development strategy for external innovation and investments, and to help guide BeiGene’s growth strategies for internal portfolio compounds. Prior to joining BeiGene, Dr. Jaggi served in various clinical evaluation and clinical development leadership roles at Novartis for approximately 10 years. Most recently, as Vice President and Global Head of Oncology Clinical Evaluation, he led the scientific and strategic evaluation for both the internal oncology pipeline as well as external innovation. At Novartis, he spearheaded the scientific and clinical evaluation of the company’s multiple partnerships including the notable acquisitions of GSK Oncology, AAA, Endocyte, CoStim, and Admune, as well as strategic investments in CAR-T therapy and multiple in-licensing agreements. Dr. Jaggi also served as the Global Clinical Program Head for Oncology Biosimilars, overseeing an integrated clinical development team across Sandoz and Novartis. Before Novartis, he worked in various clinical development roles at Bristol Myers Squib and Pfizer. Dr. Jaggi received his medical degree from Grant Medical College in Mumbai, and a Ph.D. in Pharmacology from Weill Cornell Medical College and Memorial Sloan Kettering’s joint program. He was a Ludwig Center for Cancer Immunotherapy fellow at Memorial Sloan Kettering Cancer Center.

Geoffrey Kim, M.D. joined BeiGene in August 2019 as Vice President, Applied Innovation, leading the creation and incubation of technological solutions to increase patient access to clinical trials and novel therapeutics. Prior to his appointment at BeiGene, Dr. Kim served in several senior roles at AstraZeneca, including Vice President, Oncology Regulatory Science and Strategy as well as Head of Strategic Combinations in the Immuno-Oncology Franchise. Previously, Dr. Kim oversaw the evaluation and regulation of oncology drug products for breast, genitourinary and gynecologic cancers as a division director in the Office of Hematology Oncology Products at the U.S. Food and Drug Administration and worked on numerous cross-center initiatives such as companion diagnostics, dose-finding optimization strategies, and the Oncology Center of Excellence. Dr. Kim is board certified in medical oncology and internal medicine, and he completed his medical oncology fellowship at the National Cancer Institute (NCI) and his residency in internal medicine at the Montefiore Medical Center. He received his medical degree from New York Medical College and a B.S. from the University of California, Los Angeles.

Jonathan Liu, Ph.D., DVM, joined BeiGene in 2018 and currently serves as Chief Executive, Bio-Island Initiative & Chairman of the Board, BeiGene Guangzhou Biologics, Ltd. Co. He joined BeiGene from Johnson & Johnson (J&J) where he held the position of Head of China Pharmaceutical Development & Manufacturing Sciences (PDMS), responsible for PDMS operations of biologicals, small molecule drugs and vaccine development in the Asia Pacific region. Prior to joining J&J Dr. Liu spent more than 20 years in the industry and has led many drug development projects in CMC, manufacturing, R&D and production facility management, and has contributed to the successful launch, clinical studies and/or other major milestones for ReFacto^®，BENEFIX^®，FluMist^®, ACAM2000^® and 20 other drug products for Pfizer, Sanofi, AstraZeneca and Novartis. His ACAM project team completed the entire drug development cycle from discovery to commercialization and national strategic stockpiling in less than five years. In addition, he is a co-author of Quality by Design for Vaccine, a white paper to the U.S. FDA on behalf of the vaccine industry. He has authored or co-authored prolifically, on subjects including the highest volumetric vaccine manufacturing process, and more than 150 scientific book chapters, lectures, journal articles in Nature, Proceedings of the National Academy of Sciences (PNAS) and has more than 20 inventions patented in the U.S., Europe, Japan, Australia and other countries.

Dr. Liu holds Ph.D. and DVM degrees from Queen’s University in Canada, and from the Hunan Agricultural University in China, respectively. He completed his post-doctoral fellowship in Harvard Medical School. He has been a member of Advisory Board or board of directors for the United States National Center of Therapeutics Manufacturing, investment firms, biotech companies, various trade organizations and scientific journal review boards.

Lily Liu joined BeiGene in June 2019 as VP, Head of Marketing, Greater China, with over two decades of experience in the pharmaceutical industry. Prior to BeiGene, Ms. Liu was VP, Head of the Specialty Care business unit at Takeda in China, responsible for turning around the Enatone business and introducing the new product Ninlaro, which made the China national reimbursement drug list (NRDL) only five months after approval. Previously, she served as Sales Head of Oncology, Immunology, and Rare Disease at Pfizer, taking Xalkori to become the number one product for Pfizer Oncology and also successfully launched Xeljanz. Before that, Ms. Liu held a range of positions in marketing and market access at Janssen China and at their U.S. headquarters. She has a medical degree in Pediatric Medicine from Capital Medical University.

Josh Neiman joined BeiGene in July 2018 and currently serves as Chief Commercial Officer, North America and Europe. Mr. Neiman is responsible for building and leading the commercial team and operations that will bring BeiGene’s innovative medicines to patients. Mr. Neiman has broad U.S. and global oncology experience that spans marketing, sales, market access, lifecycle management, data and analytics. Most recently, Mr. Neiman was Vice President, Marketing at Flatiron Health from 2014 through its acquisition by Roche in 2018. Previously, Mr. Neiman served in a progression of commercial leadership roles at Onyx Pharmaceuticals and Genentech, Inc. where he was responsible for multiple aspects of commercialization for Kyprolis^® (carfilzomib), Rituxan^® (rituximab), Gazyva^® (obinutuzumab), and Herceptin^® (trastuzumab). Early in his career, Mr. Neiman worked as a research associate in drug discovery at Tao Biosciences and Plexxikon. Mr. Neiman received his MBA from the Kellogg School of Management at Northwestern University and his B.A. from the University of California, Berkeley, in Molecular and Cell Biology.

Jason Radford joined BeiGene in March 2020 as Senior Vice President, Business Transformation, responsible for optimizing the company’s business functionality and leading company-wide strategic initiatives to support continued growth and success. Prior to his appointment at BeiGene, Mr. Radford served on the executive leadership team of Genomic Health as general counsel leading the global legal, regulatory, and compliance functions. Previously, Mr. Radford was on the legal leadership team at Life Technologies, now a part of Thermo Fisher Scientific, where he was lead counsel of the Medical Sciences business division and supported strategic business transformation initiatives, including new acquisitions and business integrations. Mr. Radford holds a J.D. and an MBA from Boston College and a B.A. from University of California, Los Angeles.

Scott Samuels, Esq., has served as our Senior Vice President, General Counsel since May 2017. Prior to joining us, Mr. Samuels served as Assistant General Counsel and Acting General Counsel and Secretary at ARIAD Pharmaceuticals, Inc., from 2016 through its acquisition in 2017 by Takeda Pharmaceuticals. Previously, Mr. Samuels spent 17 years in private practice at the law firm Mintz Levin, including nine years as a partner in the firm’s life sciences practice, where he specialized in securities law, corporate governance, and business development and corporate financing transactions. Mr. Samuels began his career as a law clerk in the U.S. District Court in Philadelphia. Mr. Samuels received his J.D. from George Mason University and his Bachelor of Arts in Philosophy from Cornell University.

Michael H. Schoen joined BeiGene in August 2017 and is the Chief of Staff to CEO John Oyler and Senior Vice President, Business Operations. Prior to joining BeiGene he was Managing Director & Head of Latin America & Caribbean Debt Capital Markets for Scotiabank. Mr. Schoen also worked at Credit Suisse, DLJ, and J.P. Morgan in their respective Emerging Markets groups. Mr. Schoen graduated from the Massachusetts Institute of Technology with a B.S. in Management from the Sloan School of Management. He is also the Chairman of the Board of Directors of the HealthCare Chaplaincy Network, a global health care nonprofit organization that offers spiritual care-related information and resources, and professional chaplaincy services in hospitals, other health care settings, and online.

Gary Wang has served as our Vice President of Human Resources, APAC, and Co-Lead of our Global HR function since April 2018. Prior to joining BeiGene Gary was at Johnson & Johnson from 2010 to 2018, where he served various HR leadership positions. From 2017 to 2018, he was the head of the HR business unit of the company’s R&D organizations and J&J Innovation Asia Pacific. From 2012 to 2017, he was Head of Talent Acquisition China when he built up the China Talent Acquisition team of J&J. From 2010 to 2012, he was the senior HR Business Partner in Janssen, the pharmaceutical company of J&J. Prior to healthcare industry at Johnson & Johnson, Gary spent about 10 years in technology industry, from 2008 to 2010, he served as the head of HR Asia at The MathWorks, a Boston based software company. From 2004 to 2008, Gary was at Symantec, where he was the HR manager of China Development Center. From 2001 to 2004, Gary was at the BEA Systems Inc, as the HR supervisor. Gary received his Bachelors’ Degree of Economics from Beijing Institute of Tourism and his EMBA from the Tsinghua University.

Anita Wu joined BeiGene in June 2019 as SVP, Chief Commercial Officer, Greater China, bringing more than 20 years of industry experience to the Company. Most recently, Ms. Wu served as General Manager of the Specialty Care business unit at Sanofi China. While at Sanofi, she drove impressive revenue growth. While there she successfully launched Aubagio, a multiple sclerosis product, which set records at Sanofi for new product launch timeline and launch excellence. Ms. Wu played an important role in shaping rare disease policy as the RDPAC Rare Disease group co-chair and a key member of the China Rare Disease Alliance. Prior to Sanofi, Ms. Wu held several leadership positions at AstraZeneca China, including Head of the Diabetes business unit, as well as sales and marketing roles in the Oncology business unit. There, she successfully launched Iressa in first-line and set up the first dedicated biomarker testing team in China to solidify the drug’s leadership in lung cancer. Ms. Wu also worked for Pfizer in China and the U.S., Genzyme, and Eli Lilly. She holds a BS in Environmental Engineering from Shanghai University.

Wendy Yan is our Senior Vice President and has served as Chief Regulatory Officer since 2014. From 1996 to 2014, Ms. Yan held senior Regulatory Affairs positions at GlaxoSmithKline, AstraZeneca, and Bayer. She was the Director, Head of Regulatory Affairs at GSK. At Bayer, she served as the Head of Regulatory Affairs, then Global Regulatory Strategist at Global R&D Center. From 1988 to 1995, Ms. Yan was the chief pharmacist at Beijing Drug Control Institute, a subordinate organization of former CFDA. Ms. Yan received her M.D. from Beijing Traditional Chinese Medicine University and MBA from Staffordshire University (UK).

Todd Yancey, M.D., is our Senior Vice President, Global Medical Affairs and New Market Development. Dr. Yancey joined BeiGene in February 2017 as Senior Vice President, Global Clinical Development for Immuno-Oncology where he was instrumental in developing the global solid tumor clinical program and organization. Dr. Yancey has been a physician for over 30 years and has spent the majority of that time in roles of increasing seniority in international biotechnology Clinical Development and Medical Affairs. He has served in a leadership role for the development or launch of seven registered Oncology therapeutics. Previously, Dr. Yancey was Group Vice President of Global Medical Affairs at BioMarin; SVP of Global Medical Affairs at Clovis Oncology; VP of Global Medical Affairs at Medivation; and SVP of Clinical Development at Onyx. Dr. Yancey received his M.D., from the University of Virginia School of Medicine and his Bachelor of Arts in Biology and Psychology also from the University of Virginia. He completed his residency in Internal Medicine at The New York Hospital, Memorial Sloan Cancer Center and his fellowship in General Internal Medicine and HIV infection at Cornell University.